Tennessee Legislation Targets Pharmacy Benefit Managers: What You Need to Know

The landscape of pharmacy operations in Tennessee is facing a significant shift following the passage of new state legislation aimed at pharmacy benefit managers (PBMs). As the healthcare industry grapples with rising drug costs and complex supply chains, this move by Tennessee lawmakers places a spotlight on the controversial business models of major healthcare conglomerates.

Understanding the New Legislation

In April 2026, the Tennessee legislature passed a bill that prohibits a pharmacy from owning a pharmacy benefit manager. PBMs act as intermediaries between insurance companies and pharmacies, negotiating drug prices and managing prescription benefit programs. By banning the common practice of vertical integration—where a single entity owns both the pharmacy and the PBM—the state is attempting to address concerns regarding market consolidation and reimbursement practices.

The legislation stems from findings by the Tennessee Department of Commerce and Insurance, which conducted an audit revealing that PBMs often reimbursed partner pharmacies at rates significantly higher than those paid to non-affiliated pharmacies. This disparity has raised questions about fair competition and the overall cost of prescription medications for consumers.

The Impact on CVS Health

CVS Health currently stands as the only company in Tennessee that operates as a pharmacy, a PBM (CVS Caremark), and an insurance provider (Aetna). Because of this unique structure, the new law directly challenges the company’s operational model in the state.

CVS has expressed strong opposition to the bill, indicating that it could necessitate the closure of 134 pharmacies across Tennessee. The company has announced plans to file a lawsuit to block the legislation, mirroring legal challenges it has initiated in other states. Similar laws passed in Arkansas in 2025 faced immediate litigation, with a federal judge ultimately blocking the enforcement of those regulations while the case continues through the court system.

Industry Consolidation and Healthcare Costs

The PBM market is highly concentrated, with a little group of companies controlling a vast majority of the industry. According to data from the health policy research organization KFF, three major companies—CVS, Cigna, and UnitedHealth—manage nearly 80% of the market. Because these organizations often function as both insurers and PBMs, critics argue that the lack of transparency in drug pricing and reimbursement creates an uneven playing field for independent and non-affiliated pharmacies.

Key Takeaways

• Regulatory Shift: Tennessee has passed a law banning the ownership of a pharmacy by a pharmacy benefit manager.
• Market Impact: The legislation specifically affects CVS Health, which maintains an integrated model of insurance, PBM services, and physical pharmacy locations.
• Legal Challenges: CVS has signaled its intention to sue the state, citing concerns over business operations and potential pharmacy closures.
• Broader Context: The move reflects a growing national trend of state-level scrutiny regarding PBM influence on healthcare costs and pharmacy reimbursement rates.

Looking Ahead

The conflict between Tennessee lawmakers and CVS highlights a broader national debate over the role of PBMs in the American healthcare system. As the legal battle unfolds, the primary concern for many patients remains the accessibility and affordability of their medications. While proponents of the bill argue that it will foster a more competitive and equitable marketplace, the potential closure of pharmacy locations serves as a reminder of the complex logistical challenges involved in regulating massive healthcare intermediaries. Patients are encouraged to monitor updates from their local pharmacies as this legal situation develops.